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CASE PRESENTATION
An 80-year-old African American woman with a past
medical history of type II diabetes mellitus, hypertension,
bilateral knee replacements and peripheral vascular
disease presented to the nephrology clinic for evaluation
of an elevated serum creatinine. Six weeks earlier she
underwent removal of a total knee prosthesis due to
septic arthritis with coagulase-negative staphylococci. A
vancomycin and tobramycin-impregnated cement spacer
block was mixed in the operating room and implanted.
Her serum creatinine concentration (sCr) was 0.9 mg/dl
upon hospital discharge. Periodic laboratory studies
performed at the nursing facility showed a steady increase
in sCr to 1.6 mg/dl at 2 weeks and then to 3.7 mg/dl by
6 weeks (Figure 1). One week before to presentation at the
nephrology clinic, she began to develop uremic symptoms
including nausea, vomiting, a metallic taste, and muscle
cramps. Her furosemide and lisinopril had been held for
3 weeks due to her rising serum creatinine with no
improvement. Her medications on presentation were
insulin, omeprazole, synthroid, metoprolol, multivitamin,
clopidogrel, atorvastatin, amlodipine, warfarin and
minocycline. The minocycline had been initiated after she
completed a 2-week course of intravenous vancomycin.
Other than the warfarin, minocycline and intravenous
vancomycin, she was on no new medications. There was
no documented history of hypotension and she took no
non-steroidal, herbal or over-the-counter medications.
Physical examination revealed that she was afebrile,
her blood pressure was 124/73 mmHg and pulse was
73 beats/min. She was alert and conversant. There was
pitting edema of the lower extremities to the knee, but
the lungs were clear to auscultation. No rashes or joint
abnormalities were noted. She did not have asterixis. She
had no auditory or vestibular symptoms although these
were not formally tested. Laboratory studies are shown in
Table 1. Her urinalysis revealed a specific gravity of 1.013,
pH of 5.0, no protein or blood, and a positive spot
leukocyte esterase with 2–5 white blood count per high
powered field. Urine microscopic analysis by the
nephrology consult team revealed few renal tubular
epithelial cells and scant granular casts without red blood
cells. She remained non-oliguric during her first few days
of her admission. Based upon her clinical presentation,
tobramycin toxicity from her knee cement spacer was
suspected. Since this diagnosis would entail surgical
treatment, a transjugular renal biopsy was performed for
confirmation (Figures 2, 3).
RENAL BIOPSY FINDINGS
The biopsy consisted of 2 fragments with 20 glomeruli
present for examination of which 5 were sclerotic (Figure 2).
The architecture of the kidney was preserved with focal
interstitial scarring. The tubules were vacuolated with
blebbing. There was arterial and arteriolar nephrosclerosis.
The glomeruli showed focal global sclerosis. Immunofluor-
escence staining for immunoglobulin A, immunoglobulin G,
immunoglobulin M, C3, C4, fibrinogen, k, or l light chains
was negative. Electron microscopy (Figure 3) demonstrated
that the glomerular architecture was well preserved with
normal basement membranes, epithelial cell foot processes,
and endothelial fenestrations. There were no electron-dense
deposits. Within the cytoplasm of the proximal tubule cells,
lysosomal swelling is observed with myeloid bodies present.
DIAGNOSIS
Acute tubular necrosis secondary to aminoglycoside exposure
superimposed on hypertensive nephrosclerosis.
CLINICAL FOLLOW UP
She was admitted to the hospital where hemodialysis was
initiated. Despite hemodialysis treatments, her serum tobra-
mycin level continued to rebound (Figure 1). Surgeons
removed her antibiotic-impregnated cement spacer and her
serum tobramycin became undetectable. Unfortunately, she
remains dependent on hemodialysis 5 months later.
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DISCUSSION
Aminoglycosides are well known to induce nephrotoxicity.
The incidence varies from 7 to 36% and increases with the
duration of therapy.1 Clinically, aminoglycoside nephrotoxi-
city frequently presents as nonoliguric acute tubular
necrosis.2 It can also present in a variety of electrolyte
abnormalities (Table 2).3–6 Risk factors for aminoglycoside
nephrotoxicity include a baseline-elevated serum creatinine
(sCr), increased duration of therapy, and an elderly age.7
Other potential risk factors include shock, liver disease,
hypotension, elevated levels of the aminoglycoside, female
sex, and low serum albumin concentration.8,9 Coadministra-
tion of vancomycin and a more frequent dosing regimen have
been shown to be associated with the development of
nephrotoxicity.10
Renal excretion of aminoglycosides is the sole method of
elimination of the drug from the plasma and aminoglycosides
are known to be freely filtered by the glomeruli and excreted
by the kidney unchanged.1 However, aminoglycosides are
reabsorbed by proximal tubular epithelial cells and accumu-
late locally to levels beyond what is observed in the plasma.
This high local concentration of drug in the proximal tubule
leads to nephrotoxicity.11,12 Vancomycin may enhance
binding of aminoglycosides to the brush border membranes
and enhance absorption into the proximal tubule cells.10
Reabsorption of aminoglycosides, and hence its nephro-
toxicity, is mediated by binding to acidic phospholipids and
uptake is facilitated by the endocentric receptor megalin, also
known as gp330.12,13 Megalin belongs to the superfamily of
low-density lipoprotein receptors and is responsible for the
uptake of many proteins.14 Megalin was established to have a
crucial role in the uptake of aminoglycosides into proximal
tubular epithelial cells by the usage of animal models.
Knockout animals in which megalin expression was disrupted
were noted to have reduced accumulation of aminoglycosides
into proximal tubular epithelial cells relative to wild-type
animals.15 Maleate, a substance that impairs uptake of
megalin-mediated ligands by inducing megalin shedding,
has also been shown to prevent uptake of aminoglycosides
into proximal tubule epithelial cells.11 As uptake is mediated
by an endocytic process rather than diffusion, aminoglyco-
side uptake appears to be saturable at clinically relevant
levels. This is important as once-daily dosing leads to less
renal accumulation of aminoglycosides than a continuous
infusion of the drug at the same concentration.16
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Figure 1 | A graph showing the patient’s gradual rise in
creatinine after her hospitalization when she had the
tobramycin-impregnated cement implanted into her knee.
Hemodialysis was initiated after she was readmitted, on day 45
(arrow). Tobramycin levels were notably persistently elevated until
she underwent a second surgery on day 63 (arrowhead) to extract
her tobramycin-impregnated knee implant.
Table 1 | Serum laboratory values at the time of presentation
to renal clinic
Serum laboratory test Conventional units SI units
Sodium 144 mequiv./l 144 mmol/l
Potassium 4.7 mequiv./l 4.7 mmol/l
Bicarbonate 14 mequiv./l 14 mmol/l
Blood urea nitrogen 74 mg/100 ml 26.4 mmol/l
Creatinine 3.7 mg/100 ml 282mmol/l
Calcium 8.4 mg/100 ml 2.1 mmol/l
Albumin 2.9 g/100 ml 29 g/l
Magnesium 2.0 mg/100 ml 0.82 mmol/l
Phosphorus 5.4 mg/100 ml 1.74 mmol/l
White blood count 10.5 103 per ml 10.5 109 per l
Hemoglobin 10.7 g/100 ml 107 g/l
Tobramycin 1.4mg/ml —
Figure 2 | Light microscopy showing diffuse vacuolization in
the proximal tubular cells (arrows). There is tubular cell dropout
with blebbing (arrowheads) suggestive of acute tubular necrosis.
Glomeruli (star) show global sclerosis (hematoxylin and eosin
Original magnification  40).
Figure 3 | Electron microscopy of kidney biopsy showing
myeloid bodies (arrows) consistent with a diagnosis of
aminoglycoside-induced nephrotoxicity.
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Once-daily aminoglycoside therapy or consolidated ther-
apy has been clinically validated in many studies as being
associated with less nephrotoxicity than the standard multi-
ple-daily dosing regimens.17 It has been well described that
the area under the curve is an important determinant of
nephrotoxicity, with once-daily dosing having a lower
probability of inducing nephrotoxicity with similar area
under the curve’s as three times a day dosing.18 This is
because the constant exposure of the kidney to the
aminoglycoside saturates uptake through limited transporters
as previously described. A continuous low level can be more
nephrotoxic than a high level that is associated trough and
peak variability. Delivering a higher dosage of aminoglyco-
sides at an extended dosing interval may induce less
nephrotoxicity as uptake is saturated and the excess of
aminoglycosides that is filtered by the glomeruli is freely
excreted.11,19
After renal tubular epithelial cells take up aminoglyco-
sides, the mechanism of nephrotoxicity is not fully under-
stood. It is likely partially mediated by accumulation of drug
in lysosomes. This accumulation induces lysosomal swelling,
which leads to phospholipidosis and eventual apoptosis of
the renal tubular epithelial cells. This process can be
visualized by electron microscopy where myelin-like struc-
tures or myeloid bodies form, as seen in our patient
(Figure 3). The presence of myeloid bodies visualized by
electron microscopy is thought to be specific for a toxic
etiology of acute tubular necrosis rather than an ischemic
etiology.20
Total joint replacement is a routine operation in
orthopedics with an infection rate of 0.5–3% of cases.21
Using antibiotic-impregnated cement to treat these artificial
joint infections is associated with a higher success rate than
nonimpregnated cement and has become the standard of care
for patients with an infection at the site of a joint
replacement.21 The theory behind using an aminoglycoside-
impregnated cement is that it delivers high levels of
antibiotics at the site of joint infection while avoiding
systemic side effects.22 This method of drug delivery takes
advantage of the known concentration-dependent bacterici-
dal effect of aminoglycosides. Patients avoid systemic
exposure by having high local aminoglycoside concentrations
with low systemic concentrations.
Drug elution from an impregnated spacer is known to be
greatest within the first 24 h, and then rapidly tapers.23 One
case series reported no nephrotoxicity, but it was only 36
patients.23 Another series reported on the pharmacokinetics
of one commercially available tobramycin bone cement in 10
patients. The mean serum tobramycin concentration with
this compound peaked at 0.94 mg/l and declined to 0.2 mg/l
by 48 h.24 In 10 patients with gentamicin-impregnated
spacers, the peak blood concentration was 0.12 mg/l.25 Our
patient had higher levels of tobramycin than reported in the
above series. This was also true in other case reports.26–28 The
variability in serum levels may be related to manufacturing
differences between brands, variability in those compounds
mixed by hand in the operating room (as was true in our
patient) or to patient-specific factors. Despite the relatively
low serum concentrations of tobramycin, these patients have
a high area under the curve given the continuous excretion of
tobramycin from the cement spacer.
In our patient, measurable serum levels persisted, despite
the initiation of hemodialysis treatments, until the spacer was
removed. She may also have been at increased risk because of
advanced age, medical comorbidities, and concurrent use of
vancomycin. The observation of myeloid bodies in our
patient’s renal biopsy confirmed our suspicion of aminogly-
coside-induced nephrotoxicity.
CONCLUSION
We report the first case of biopsy-proven aminoglycoside
nephrotoxicity from an antibiotic-impregnated cement
spacer. Clinicians should be aware that aminoglycoside-
induced acute tubular necrosis might occur and follow sCr
measurements in high-risk patients. If patients develop
kidney injury after surgery, aminoglycoside levels should be
monitored and the cement may need to be removed.
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